Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene

1. Primary purpose To evaluate disease free survival rate (DFS) after taking 36 months with Letrozole in postmenopausal women with hormone receptor positive breast cancer who complete 5 years of Toremifene 2. Secondary purpose * To evaluate follows after taking 36 months with Letrozole in postmenopausal women with hormone receptor positive breast cancer who complete 5 years of Toremifene. 1. Disease Free Survival rate(DFS)-12 months, 24 months 2. Distant disease free survival rate(DDFS), Overall Survival(OS) * 12 months, 24 months, 36 months c. safety * Change of lipid profiles * Mortality and morbidity due to Cardiovascular disease * Incidence of Fracture * Change of Bone density * Common toxic effect